Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
3(75%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_4
2
50%
Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Recruiting2
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 42 (66.7%)

Trials by Status

recruiting250%
active_not_recruiting125%
completed125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_2

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

NCT04608630
recruitingphase_4

Preserving Geriatric Muscle With an Osteoporosis Medication

NCT06118905
active_not_recruitingphase_4

PRevEnting FracturEs in REnal Disease - 1

NCT05096195
completed

Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients

NCT04702204

Clinical Trials (4)

Showing 4 of 4 trials
NCT04608630Phase 2

Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

Recruiting
NCT06118905Phase 4

Preserving Geriatric Muscle With an Osteoporosis Medication

Recruiting
NCT05096195Phase 4

PRevEnting FracturEs in REnal Disease - 1

Active Not Recruiting
NCT04702204

Efficacy of Denosumab Treatment in Bisphosphonate Unresponsive Patients

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4